FDA warning letter December 2025
-
Business

FDA Recall of Compounded Tirzepatide Highlights Quality Risks in Gray-Market GLP-1 Supply
A North Carolina compounding pharmacy already censured by federal regulators for sterile-production failures is recalling nearly two dozen vials of…
Read More »
